The Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Brigham Cancer Center has been a leader in cellular therapies since our program's founding in 1972. Our stem cell transplantation program is one of the largest and most experienced transplant centers in the world, with outcomes that consistently exceed expected outcomes established by the Center for International Blood and Marrow Transplant Research (CIBMTR). Our program is also at the forefront of emerging cellular therapies that help the immune system fight cancer such as CAR T-cell therapy, cancer vaccines, NK cell therapy, and genetically-modified immune cells.
Division of Stem Cell Transplantation and Cellular Therapies
Adult Stem Cell Transplant Program
Our Adult Stem Cell Transplant Program is one of the largest and most experienced in the world. We offer autologous and allogeneic stem cell transplant for adult patients with a variety of hematologic malignancies, bone marrow failure syndromes, and rare and congenital blood disorders.
Cellular Therapies Program
Our Cellular Therapies Program is at the forefront of novel cellular therapies that help the immune system fight cancer such as CAR T-cell therapy, cancer vaccines, NK-cell therapy and other genetically-modified T cells.
Connell and O'Reilly Families Cell Manipulation Core Facility
The Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) is a critical component of our cellular therapies program, processing almost 1,400 cellular products each year, including cells for more than 600 adult and pediatric stem cell transplants. The CMCF also supports more than 40 diverse active clinical research protocols, with a focus on translational research in stem cell transplantation and immune therapy for cancer. It is among the largest cellular therapies labs at an academic medical center and New England's only Class 10,000 Good Manufacturing Practices (GMP) cellular manufacturing facility.